AQP4 and autoimmune disease: In multivariate analysis, after adjusting for factors such as age at onset, sex, AQP4 antibody status, site of onset, pre-treatment ARR, pre-treatment disease duration, corticosteroid maintenance therapy, comorbid autoimmune diseases, and pre-treatment EDSS score, no significant differences were observed between the RTX group and the other groups.